Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × Brentuximab Vedotin × 1 year × Clear all

Sponsor

Conditions

Hodgkin Disease 16 Lymphoma 6 Lymphoma, T-Cell, Cutaneous 5 Lymphoma, T-Cell 5 Mycosis Fungoides 4 Lymphoma, T-Cell, Peripheral 4 Lymphomatoid Papulosis 3 Lymphoma, Large-Cell, Anaplastic 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, Primary Cutaneous Anaplastic Large Cell 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Immunoblastic Lymphadenopathy 2 Hematologic Diseases 2 Enteropathy-Associated T-Cell Lymphoma 2 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Mesothelioma, Malignant 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1 Leukemia, Large Granular Lymphocytic 1 Leukemia 1 Carcinoma, Non-Small-Cell Lung 1 Ann Arbor Stage IIB Hodgkin Lymphoma 1

Interventions

fludarabine 4 Cisplatin 4 Pemetrexed 3 Cyclophosphamide 3 pralsetinib 2 pembrolizumab 2 fludarabine phosphate 2 durvalumab 2 cobimetinib 2 atezolizumab 2 Whole-Body Irradiation 2 Vemurafenib 2 Tacrolimus 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Paclitaxel 2 Nivolumab 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Busulfan 2 130-nm albumin-bound paclitaxel 2 trametinib 1 spartalizumab 1 ruxolitinib 1 repotrectinib 1 ponatinib 1 pertuzumab 1 gilteritinib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡